Mergers, acquisitions and related transactions in the life sciences sector require experienced legal advisors well versed in the issues facing companies in this highly regulated industry. A global footprint is likewise mandatory, as cross-border transactions are becoming a standard element of virtually any effective, long-term corporate strategy.
McDermott’s corporate transactional lawyers in the United States and Europe, in conjunction with MWE China Law Offices, have successfully negotiated and closed hundreds of deals on behalf of life sciences businesses worldwide. Ranked nationally for M&A, health and life sciences by Chambers USA and The Legal 500, we counsel clients whose products include medical devices, biotechnology and pharmaceuticals. The size and scope of our clients’ operations are equally broad; we represent start-ups, large multinationals, and venture capital, private equity and large public investor funds with equal skill and dedication.
The options to achieve corporate growth are abundant. The M&A lawyers at McDermott have demonstrated success representing life sciences clients across a wide range of transaction types to achieve growth strategies. For established players in the market, we have led large traditional M&A deals, advised strategic buyers in pursuit of distressed assets, and executed a client’s growth strategy through spin-offs, carve-outs and divestitures as well as led private equity-funded buyouts, venture capital funding, or deals with universities, academic medical centers and research institutions.
Our substantial M&A and commercial transactions capabilities, complimented by our deep industry, regulatory and IP knowledge, provide for a superior platform for strategic growth in the United States and abroad. We take a cost-effective approach to deal management, often utilizing legal project management best practices along with our proprietary portal technologies to consistently execute transactions on time and within budget.